<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05086107</url>
  </required_header>
  <id_info>
    <org_study_id>BV100-003</org_study_id>
    <nct_id>NCT05086107</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment</brief_title>
  <official_title>An Open-label, Non-randomized, Monocenter, Single-dose, Phase I Study to Evaluate Pharmacokinetics and Safety of BV100 Administered as Single Intravenous In-fusion to Subjects With Renal Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioVersys AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CRU Hungary Kft</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CRU Hungary Early Phase Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>BioVersys AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the pharmacokinetics (PK) of rifabutin in subjects with renal impairment after&#xD;
      single intravenous (IV) infusion of BV100&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate the pharmacokinetics (PK) of rifabutin and excipient in subjects with renal&#xD;
      impairment after single intravenous (IV) infusion of BV10=. In addition to investigate the&#xD;
      safety and tolerability of BV100 in subjects with renal impairment and to investigate the PK&#xD;
      of 25-acyl-rifabutin metabolite in subjects with renal impairment after single intravenous&#xD;
      (IV) infusion of BV100&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>BV100 administered as a single intravenous infusion to subjects with varying degree of renal impairment and control volunteers with normal renal function.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate the pharmacokinetics (PK) of rifabutin in subjects with renal impairment</measure>
    <time_frame>96 hours</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To characterize the single dose pharmacokinetic profile of rifabutin</measure>
    <time_frame>96 hours</time_frame>
    <description>Peak Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the safety and tolerability of single intravenous ascending doses of BV100 assessed by the nature, occurrence, and severity of treatment-emergent adverse events</measure>
    <time_frame>7 days</time_frame>
    <description>Safety and Tolerability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the plasma concentration of the main metabolite 25-O-Desacetyl-Rifabutin in plasma in subjects with renal impairment</measure>
    <time_frame>96 hours</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects with mild renal impairment (eGFR: 60 to 89 mL/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects with moderate renal impairment (eGFRr: 30 to 59 mL/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects with severe renal impairment (eGFR: 15-29 mL/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects with normal renal function (eGFR: ≥ 90 mL/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects with end stage renal disease (ESRD) eGFR: &lt;15 mL/min requiring dialysis (with BV100 dosing and PK during the dialysis-free interval)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects with ESRD (eGFRr: &lt;15 mL/min) requiring dialysis (with BV100 dosing and PK on the day of dialysis)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BV100</intervention_name>
    <description>Rifabutin for infusion</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <other_name>Rifabutin for Infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects who are able to understand and follow instructions during the study.&#xD;
&#xD;
          2. Subjects who signed informed consent.&#xD;
&#xD;
          3. Male subjects ≥18 and ≤75 years of age; female subjects ≥18 and ≤75 years of age of&#xD;
             non-childbearing potential, defined as follows:&#xD;
&#xD;
               -  female subjects 50 years of age or older, in menopause for 24 consecutive months,&#xD;
                  and not receiving any hormone replacement therapy within 24 months prior to&#xD;
                  inclusion into the study&#xD;
&#xD;
               -  female subjects who underwent surgical sterilization&#xD;
&#xD;
               -  female subjects who underwent hysterectomy&#xD;
&#xD;
               -  female subjects with documented premature ovarian failure&#xD;
&#xD;
          4. Weight within a BMI range of 19.0-35.0 kg/m2, range limits inclusive.&#xD;
&#xD;
          5. Having had no febrile or infectious illness for at least 7 days prior to dosing.&#xD;
&#xD;
          6. The subject will be available to complete the study.&#xD;
&#xD;
          7. The subject commits to comply with the restrictions and requirements of the protocol&#xD;
             and, in the opinion of the study physician, will be able to complete the study.&#xD;
&#xD;
             Control volunteers with normal renal function, in addition to criteria of &quot;All&#xD;
             subjects&quot;:&#xD;
&#xD;
          8. Estimated glomerular filtration rate (eGFR) according to MDRD:&#xD;
&#xD;
               -  ≥90 mL/min (normal renal function)&#xD;
&#xD;
          9. Control subjects have to be in good health or in stable condition, in the opin-ion of&#xD;
             the study physician, as determined by medical history, ECG, vital signs, physical&#xD;
             examination, and clinical laboratory tests. Subjects having chronic conditions should&#xD;
             have an onset of at least 3 months prior to Screening, clini-cally stable, and&#xD;
             well-controlled.&#xD;
&#xD;
             Renally impaired patient volunteers, in addition to criteria of &quot;All subjects&quot;:&#xD;
&#xD;
         10. Estimated glomerular filtration rate (eGFR) according to MDRD:&#xD;
&#xD;
               -  60-89 mL/min (mild renal impairment)&#xD;
&#xD;
               -  30-59 mL/min (moderate renal impairment)&#xD;
&#xD;
               -  15-29 mL/min (severe renal impairment)&#xD;
&#xD;
               -  &lt;15 mL/min (requiring dialysis)&#xD;
&#xD;
         11. Stable renal impairment, defined as no clinically significant change in dis-ease&#xD;
             status within 2 weeks from Screening, as judged by the Investigator.&#xD;
&#xD;
         12. Subjects with systolic blood pressure ≥ 90 mmHg and diastolic blood pressure ≥ 50&#xD;
             mmHg.&#xD;
&#xD;
         13. Patients with chronic diseases / conditions other than renal impairment can be&#xD;
             included, provided that these diseases / conditions are stable, well-controlled, and&#xD;
             do not interfere with the study objectives or the subject's over-all safety, as judged&#xD;
             by the Investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unwilling or unable to give informed consent.&#xD;
&#xD;
          2. As a result of the medical screening process, the study physician considered the&#xD;
             subject unfit for the study.&#xD;
&#xD;
          3. Pregnant or lactating women or men with female partners who are lactating or are&#xD;
             pregnant.&#xD;
&#xD;
          4. Known or suspected history of hypersensitivity to rifabutin or excipients or to drugs&#xD;
             of a similar chemical class including rifampicin, rifapentine, rifaximin; history of&#xD;
             allergic reactions leading to hospitalisation or any other allergic con-ditions&#xD;
             (including drug allergies, asthma, eczema, anaphylactic reactions but excluding&#xD;
             untreated, asymptomatic, seasonal allergies) which the Investigator considers may&#xD;
             affect the safety of the subject and / or the outcome of the study.&#xD;
&#xD;
          5. History of antibiotic-associated diarrhoea within one year.&#xD;
&#xD;
          6. Subjects with significant ECG abnormalities (history, or evidence of sec-ond-degree&#xD;
             heart block of Mobitz type II, third degree heart block, or any ab-normality&#xD;
             considered relevant by the Investigator), QTcF &gt; 460 ms, PR &gt; 200 ms, or QRS duration&#xD;
             &gt; 120 ms.&#xD;
&#xD;
          7. History of symptomatic, chronic or recurrent infection (e.g. nausea, vomit-ing,&#xD;
             diarrhoea, infection with fever) or any viral, bacterial, fungal or parasitic&#xD;
             infection within 30 days prior to admission to the clinical unit.&#xD;
&#xD;
          8. A positive screening serology test for hepatitis B surface antigen (HBsAg), hepatitis&#xD;
             C virus (HCV), or human immunodeficiency virus (HIV)-1 and / or 2.&#xD;
&#xD;
          9. Positive drugs-of-abuse or alcohol screen.&#xD;
&#xD;
         10. History of epilepsy, other neurological disorders, or neuropsychiatric con-ditions.&#xD;
&#xD;
         11. History of seizures.&#xD;
&#xD;
         12. Subjects having used megadose vitamins (i.e. 20 to 600 times the recom-mended daily&#xD;
             supplement dose) within 7 days prior to dosing, unless in the opinion of the study&#xD;
             physician the medication does not interfere with the study procedures or compromise&#xD;
             safety&#xD;
&#xD;
         13. Volunteers who have received any medications, including St John's Wort, known to&#xD;
             chronically alter drug absorption or elimination processes, utilized within 30 days of&#xD;
             IMP administration.&#xD;
&#xD;
         14. Regular use within 3 months of IMP administration of a CYP3A enzyme modifier - any&#xD;
             inhibitor, moderate or strong inducer, and sensitive or moder-ately sensitive&#xD;
             substrate, as listed in Section 11.3 'Prohibited concomitant med-ications'.&#xD;
&#xD;
         15. Volunteers who have participated in a clinical study involving administra-tion of an&#xD;
             investigational drug within the following time period prior to the dosing day in the&#xD;
             current study: 30 days, 5 half-lives or twice the duration of the biological effect of&#xD;
             the investigational product (whichever is longer).&#xD;
&#xD;
         16. Volunteers who consume more than 21 units of alcohol per week, or who have a&#xD;
             significant history of alcohol abuse (one unit of alcohol equals ½ pint [285 mL] of&#xD;
             beer or lager, one glass [125 mL] of wine, or 30 mL of 40% of alcohol by volume&#xD;
             distilled spirits).&#xD;
&#xD;
         17. Excessive consumption of caffeine- or xanthine-containing food or bever-ages (&gt; 5 cups&#xD;
             of coffee a day or equivalent), or inability to stop consuming from 48 hours prior to&#xD;
             study treatment administration.&#xD;
&#xD;
         18. Subjects who smoke more than 10 cigarettes a day.&#xD;
&#xD;
         19. Any use of drugs-of-abuse or alcohol abuse within 2 years prior to the first admission&#xD;
             to the clinical unit.&#xD;
&#xD;
         20. Inability to understand or communicate reliably with the Investigator or considered by&#xD;
             the Investigator to be unable to or unlikely to co-operate with the requirements of&#xD;
             the study.&#xD;
&#xD;
         21. Any other conditions or factors which in the opinion of the Investigator may interfere&#xD;
             with study conduct. Failure to satisfy the Investigator of fitness to participate for&#xD;
             any other reason.&#xD;
&#xD;
         22. Any significant blood loss, donation of one unit (450 mL) of blood or more, or receipt&#xD;
             of transfusion of any blood or blood products within 60 days, or plasma donation&#xD;
             within 7 days prior to the first admission to the clinical study site.&#xD;
&#xD;
         23. Volunteers who are employees or immediate family members of the study site or Sponsor.&#xD;
&#xD;
             Control volunteers with normal renal function, in addition to criteria of &quot;All&#xD;
             subjects&quot;:&#xD;
&#xD;
         24. Supine systolic blood pressure &gt; 150 mmHg or &lt; 90 mmHg, or diastolic blood pressure &gt;&#xD;
             100 mmHg or &lt; 50 mmHg at Screening or on Day 1, prior to dosing (any abnormal blood&#xD;
             pressure results may be repeated arbitrarily, and if the repeat result is within the&#xD;
             normal range, it is not considered to have met the exclusion criterion). Pulse rate &gt;&#xD;
             100 or &lt; 50 beats per minute at Screening or on Day 1, prior to dosing.&#xD;
&#xD;
         25. Screening laboratory values should not exceed 1.5 x ULN, and the eventu-al deviation&#xD;
             should be deemed as being clinically non-significant. Any abnor-mal value of these&#xD;
             parameters may be repeated arbitrarily, and if the repeated result is within the&#xD;
             allowed range, it is not considered to have met the exclusion criterion.&#xD;
&#xD;
         26. Volunteers who have received any new prescribed systemic or topical medication within&#xD;
             4 weeks of the first dose administration.&#xD;
&#xD;
             Renally impaired patient volunteers, in addition to criteria of &quot;All subjects&quot;:&#xD;
&#xD;
         27. Acute renal failure (as judged by the Investigator).&#xD;
&#xD;
         28. History of kidney transplant regardless of functionality.&#xD;
&#xD;
         29. History of nephrectomy.&#xD;
&#xD;
         30. Start of any new medication or any changes to current dosages within 14 days prior to&#xD;
             study drug administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Glenn E Dale, PhD</last_name>
    <phone>+41-79-769-3983</phone>
    <email>info@bioversys.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian Kemmer, PhD</last_name>
    <phone>+41-79-769-3983</phone>
    <email>info@bioversys.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CRU Hungary Kft., Early Phase Unit</name>
      <address>
        <city>Miskolc</city>
        <zip>H-3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geza Lakner, MD</last_name>
      <phone>+36 46 798 262</phone>
      <email>lakner.geza@hungarnet.hu</email>
    </contact>
    <contact_backup>
      <last_name>Peter Kovacs, MD</last_name>
      <phone>+36 30 303 9373</phone>
      <email>pkovacs@cruint.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 8, 2021</study_first_submitted>
  <study_first_submitted_qc>October 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2021</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifabutin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

